WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H530224
CAS#: 264869-71-8
Description: SLV-310 is a novel, potential antipsychotic, combining potent dopamine D2 receptor antagonism with serotonin reuptake inhibition and 5-HT reuptake receptor inhibition. It has potential for treating a broad range of symptoms in schizophrenia.
Hodoodo Cat#: H530224
Name: SLV-310
CAS#: 264869-71-8
Chemical Formula: C25H24FN3O2
Exact Mass: 417.19
Molecular Weight: 417.484
Elemental Analysis: C, 71.92; H, 5.79; F, 4.55; N, 10.07; O, 7.66
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: SLV-310; SLV 310; SLV-310; SLV310
IUPAC/Chemical Name: 2-(4-(4-(5-fluoro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl)butyl)isoindoline-1,3-dione
InChi Key: NECJNLXOJRDELU-UHFFFAOYSA-N
InChi Code: InChI=1S/C25H24FN3O2/c26-18-7-8-23-21(15-18)22(16-27-23)17-9-13-28(14-10-17)11-3-4-12-29-24(30)19-5-1-2-6-20(19)25(29)31/h1-2,5-9,15-16,27H,3-4,10-14H2
SMILES Code: O=C1N(CCCCN2CC=C(C3=CNC4=C3C=C(F)C=C4)CC2)C(C5=C1C=CC=C5)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 417.48 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: van Hes R, Smid P, Stroomer CN, Tipker K, Tulp MT, van der Heyden JA, McCreary AC, Hesselink MB, Kruse CG. SLV310, a novel, potential antipsychotic, combining potent dopamine D2 receptor antagonism with serotonin reuptake inhibition. Bioorg Med Chem Lett. 2003 Feb 10;13(3):405-8. PubMed PMID: 12565939.
2: Lange JH, Reinders JH, Tolboom JT, Glennon JC, Coolen HK, Kruse CG. Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs. J Med Chem. 2007 Oct 18;50(21):5103-8. PubMed PMID: 17880057.
3: Jones CA, McCreary AC. Serotonergic approaches in the development of novel antipsychotics. Neuropharmacology. 2008 Nov;55(6):1056-65. doi: 10.1016/j.neuropharm.2008.05.025. Review. PubMed PMID: 18621404.
